Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Boram Han
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Related publications
A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Multicenter Phase II Study With Weekly Bendamustine and Paclitaxel as First- Or Later-Line Therapy in Patients With Metastatic Breast Cancer: RiTa II Trial
Breast Care
Surgery
Oncology
Randomized Phase II Trial of First-Line Treatment With Tailored Irinotecan and S-1 Therapy Versus S-1 Monotherapy for Advanced or Recurrent Gastric Carcinoma (JFMC31-0301)
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
P-161 * a Phase I-Trial Assessing Several Schedules of Oral S-1 Combined With Fixed Doses of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- Or Second-Line Treatment
Annals of Oncology
Medicine
Oncology
Hematology
Capecitabine and Irinotecan as First- Line Chemotherapy for Patients With Metastatic Colorectal Cancer
Journal of IMAB - Annual Proceeding (Scientific Papers)
Dentistry
"Poker" Association of Weekly Alternating 5-Fluorouracil, Irinotecan, Bevacizumab and Oxaliplatin (FIr-B/FOx) in First Line Treatment of Metastatic Colorectal Cancer: A Phase II Study
BMC Cancer
Cancer Research
Oncology
Genetics
Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-Line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Clinical Colorectal Cancer
Oncology
Gastroenterology
Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer
Molecular and Clinical Oncology
Cancer Research
Oncology
